瑞银发表研究报告指，海吉亚医疗(06078.HK) 2024年业绩逊预期，收入按年增长9.1%至44.5亿元人民币，低于市场普遍预期的52.2亿元人民币，当中去下半年收入按年下降10.9%，管理层归因于期内医保报销收紧，与行业趋势一致。公司预计2025年经营情况将有所改善，考虑到海吉亚拥有强劲现金创造能力、充足在手现金及良好并购记录，瑞银维持海吉亚医疗“买入”评级，目标价从20元下调至19.4元，今明两年盈利预测下调18%及23%。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.